Does the MOSES trial establish superiority of AT1-receptor blockers over dihydropyridine/calcium antagonists in secondary stroke prevention?
- PMID: 16397183
- DOI: 10.1161/01.STR.0000199614.67737.e0
Does the MOSES trial establish superiority of AT1-receptor blockers over dihydropyridine/calcium antagonists in secondary stroke prevention?
Comment on
-
Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).Stroke. 2005 Jun;36(6):1218-26. doi: 10.1161/01.STR.0000166048.35740.a9. Epub 2005 May 5. Stroke. 2005. PMID: 15879332 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
